Defendant Name: TherapeuticsMD, Inc. 

Defendant Type: Public Company
SIC Code: 1311
CUSIP: 88338N10

Initial Case Details

Legal Case Name In the Matter of TherapeuticsMD, Inc.
First Document Date 20-Aug-2019
Initial Filing Format Administrative Action
File Number 3-19362
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Exchange Act
• Sec 13(a)
Other
• Regulation FD

Resolutions

First Resolution Date 20-Aug-2019

Related Documents:

34-86708 20-Aug-2019 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing Civil Penalties and a Cease-and-Desist Order
On August 20, 2019, the SEC instituted settled administrative and cease and desist proceedings against TherapeuticsMD, Inc. ("TherapeuticsMD"). The SEC stated: "This matter concerns selective disclosures of material nonpublic information on two separate occasions in 2017 by TherapeuticsMD to sell-side research analysts who covered the Company. Both disclosures related to the Company's interactions with the Food and Drug Administration ("FDA") concerning potential approval of a TherapeuticsMD drug, TX-004HR."
34-86708-s 20-Aug-2019 Administrative Summary
SEC Charges TherapeuticsMD, Inc. with Violations of Regulation FD
The SEC stated that: "[It] settled charges against TherapeuticsMD, Inc., a pharmaceutical company headquartered in Boca Raton, Florida, for violations of Regulation FD in connection with its sharing of material, nonpublic information with sell-side research analysts without also disclosing the same information to the public."
2019-156 20-Aug-2019 Press Release--Administrative Proceeding
SEC Charges TherapeuticsMD With Regulation FD Violations
The SEC stated that: "[It] charged TherapeuticsMD Inc., a pharmaceutical company headquartered in Boca Raton, Florida, with violations of Regulation FD based on its sharing of material, nonpublic information with sell-side research analysts without also disclosing the same information to the public."